gene therapy, Regeneron Pharmaceuticals and deafness
Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...
This was the stock's fifth consecutive day of gains.
15h
Barchart on MSNRegeneron Pharmaceuticals Stock: Analyst Estimates & RatingsTarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have ...
On February 18, 2025, in a closely watched decision, the United States Court of Appeals for the First Circuit in United States v.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results